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Cytokine regulation of C3 gene expression and protein biosynthesis in
rat glomerular endothelial cells. Glomerular endothelial cells are an
important site of interaction with the cellular and soluble components of
inflammation. To investigate the capacity of these cells to synthesize
complement they were cloned from isolated rat glomeruli. Messenger
RNA (mRNA) was extracted from the cells, reverse transcribed and used
as the template to identify specific gene transcripts with the polymerase
chain reaction (PCR). mRNA coding for the third component of the
complement cascade (C3) was detected in unstimulated endothelial cells,
whereas no message for the fourth component (C4) could he demon-
strated. Using a semiquantitative method of PCR, we found that the
expression of C3 is up-regulated by the cytokine tumor necrosis factor-
alpha (TNF-n), but not by the cytokines interferon-gamma (IFN-y) and
interleukin 1 alpha (IL-la). The increase in levels of C3 mRNA occurred
in a time and dose dependent manner. This increase was dependent on
new protein synthesis. Production of the C3 protein was demonstrated by
radiolabeling and immunoprecipitation, and this also was stimulated by
TNF-a. tn conclusion, we demonstrate the production of C3 by microvas-
cular endothelium of glomerular origin and its stimulation by TNF-a. We
believe that this local synthesis could have a role in the pathogcnesis of
disease, however, the nature of this role at present remains unclear.
A major function of the complement cascade is the elimination
of micro-organisms and foreign antigens from the body. C3 plays
a pivotal role in both the classical and alternative pathways of
complement activation [1] leading to the assembly of the mem-
brane attack complex, opsonization of foreign material and re-
lease of chemotactic and anaphylotoxic split products. It has
become apparent that complement also has functions in the
development of the immune response [2], and is capable of either
enhancing or inhibiting both T and B cell functions as well as
facilitating antigen presentation [31. An important protective
physiological role of complement is the solubilization and removal
of immune complexes from the circulation [41. A failure of this
clearance mechanism is probably responsible for the excess of
immune complex disease seen in humans and experimental ani-
mals with complement deficiency [1
Despite the protective functions of complement its inappropri-
ate activation can lead to tissue injury in, for example, burns and
ischemia. Deposition of complement is associated with immune
complex diseases of the kidney [6] including SLE and mesangio-
proliferative, membranous and post-streptococcal glomerulone-
phritis. Results from animal models of immune-mediated renal
injury, such as Heymann nephritis, suggest that complement has a
pathogenic role in the development of these diseases [7].
The liver is the main source of circulating complement [8].
However, it is now clear that many tissues, including the kidney,
have the capacity to synthesize complement components. In cell
culture, glomerular [9, 10] and tubular epithelial cells [11, 12] and
mesangial cells [13] synthesize complement proteins under the
control of cytokines. In vivo, expression of the C3 gene is
increased during immune complex mediated disease [141 and
acute transplant rejection [15]. Similarly, in animal models intra-
renal complement gene expression and protein synthesis are seen
during the development of immune complex disease, though in
some cases these may be derived from infiltrating cells rather than
native renal cells [16].
Human umbilical vein endothelial cells (HUVEC) have been a
much studied model for macrovascular endothelial cells. They
have the capacity to synthesize the majority of all of the comple-
ment pathway components and also can be stimulated by cyto-
kines [17, 181. The physiological role of endothelial cells from
macrovascular and microvascular sites, particularly the specialized
glomerular endothelial cell, differ greatly and, therefore, the
pathophysiological role of local complement synthesis is likely to
be different. Within the micro-environment of the glomerulus,
particularly when exposed to high paracrine levels of cytokines,
the endothelial synthesis of complement, if present, might attain
sufficient levels to enhance complement-mediated endothelial cell
activation. This could have an important impact on the functional
state of the endothelial cell, including expression of pro-inflamma-
tory cytokines, adhesion molecules and pro-coagulation factors [19].
We therefore set out to explore the capacity of cultured
glomerular endothelial cells to synthesize complement compo-
nents, and to examine the regulation of complement synthesis
modulated by pro-inflammatory cytokines. By showing that gb-
merular endothelial cells can produce C3, and that TNF-a can
significantly alter the expression of C3, this suggests the possibility
of an autocrine or paracrine loop that raises the local concentra-
tion of C3 in inflammatory conditions.
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Reagents
Cell culture media, antibiotics, sera, agarose and DNA size
markers were purchased from Gibco BRL. General chemicals,
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Fig. 1. Characterization of C3 PCR product: 3%
Nusieve agarose/1 % agarose gel stained with
ethidium bromide. Lane I contains the 272 bp
PCR product from the amplification of the C34— 105 bp eDNA. Lane 2 contains the Taq I restriction
digest of the PCR product demonstrating the
105 and 167 bands predicted by the known
sequence of C3 eDNA.
trypsin-EDTA, S. aureus Protein A, proteinase inhibitors, and
cycloheximide were obtained from Sigma (Poole, UK). 35 me-
thionine and 14C labeled protein size markers were obtained from
Amersham Int. (Aylesbury, UK). Reagents for cDNA synthesis
were obtained from Pharmacia (Milton Keynes, UK) and for PCR
from Promega (Southampton, UK). Rat recombinant IFN-y,
human recombinant TNF-cs and IL-la were purchased from
Genzyme (Cambridge, MA, USA). Goat anti-rat C3 anti-sera was
obtained from Nordic Immunological Laboratories (Tilhurg,
Netherlands).
Glomerular endothelial cell culture
Glomerular endothelial cells were isolated and cloned using a
modification [20] of the method described by Elliot et a! [21].
Glomeruli were isolated from male Sprague-Dawley rats by serial
sieving and then plated onto fibronectin coated tissue culture
dishes in a 1:1 mixture of Hepatoma G2 (ATCC, Bethesda, MD,
USA) conditioned MDCB 107 medium and KI medium. Out-
growths of cells with the phenotypic appearance of endothelial
cells (small cobblestone pattern) were separated using cloning
cylinders and passaged with Trypsin-EDTA. Clones were selected
from colonies arising from single cells and grown on fibronectin
coated plates in RPMI 1640 with 10% FCS, 10% NuSerum
penicillin and streptomycin. The cells were characterized by their
morphology, possession of angiotensin converting enzyme (ACE)
activity and ability to take up di-acetyl-LDL (Biomedical Tech-
nologies Inc., Stoughton, MA, USA). ACE activity was assessed
by the captopril inhihitable release of 3H-benzoyl-phenylalanine
from 3H-benzoyl-phe-ala-pro (Vcntrex Laboratories Inc., Port-
land, ME, USA) as previously described [22].
A rat hepatoma cell line was grown on tissue culture plastic in
DMEM containing L-glutamine, 4500 mg/liter glucose, 10% FCS
and penicillin and streptomycin [23].
For cytokine stimulation pre-confluent cells were incubated in
medium with 2% FCS for six hours then in the presence of
recombinant IFN-y (100 U/ml), human recombinant TNF-a (10
ng/ml) or IL-la (10 ng/ml) for 24 hours, unless otherwise speci-
fied.
Table 1. Sequences and position of the synthetic oligonucleotides used
in the PCR reactions
Location of Length
primer in eDNA of PCR
sequence productPrimer Oligonucleotide sequence
C3-1 GACCTGCGACTGCCCTACTCT 2535-2555 272 bp
C3-2 CTGATGAAGTGGTfGAAGACG 2785-2806
C4-1 GGATCCAGCAGflTCGGAAG 2095-3114 205 bp
C4-2 ACTGGACATGGGTCGTGGAA 3208 -3299
GPI-1 GCAGAGACGGCGAAGGAGTG 678-697 470 hp
GPI-2 ATGGGGCCTGTCTGGTGGTC 1128-1147
Primer-i is identifical to the coding strand and Primer-2 is complemen-
tary to the coding strand.
RNA extraction and eDNA synthesis
Total RNA was extracted from 106 cells or from 10 mg of
homogenized rat liver by the method of Chomczynski and Saachi
[24]. In brief, cells or homogenized tissue were lysed in 4 M
guanidium thiocyanate, 25 m sodium citrate pH 7.0, 0.5%
sarcosyl and 0.1% mercaptoethanol. This was followed by phenol/
chloroform:isoamyl alcohol extraction and isopropanol precipita-
tion. RNA was quantified by absorhance at 260 nm. eDNA was
synthesized in a reaction mixture containing 5 g total RNA, 160
ng oligo (dT)1218, 500 LM of each dNTP and 200 U Moloney
murine reverse transeriptase in 20 .d solution for 90 minutes at
37°C.
PCR amplification
Primer sequences (Table 1) were based on the known sequence
of rat C3 eDNA [251 or homologous sequences of the human and
mouse genes [26, 27] when the rat gene sequence was unavailable
[C4 and glucose phosphate isomerase (GPl)]. PCR was carried
out on eDNA reflecting 0.15 .tg of total RNA with 3 U Taq
polymerase, 12.5 pmol of the 3' and 5' primers and 200 /tMofeach
dNTP in 25 jsl of a solution containing 10 mt's Tris-HCI pH 9, 50
mM KCI, 1,5 mivi MgCl2, 0.01% gelatin wt/vol and 0.1% Triton X
100 wt/vol. The PCR cycle consisted of one minute denaturation
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Fig. 2. Influence of cytokines on C3 gene expression. Stimulation of endo-
thelial cells by cytokines for 24 hours. The columns represent the C3/GPI
ratio of the PCR products scanned from ethidium bromide stained gels.
Data points represent the means of duplicate PCR reactions in three
experiments. A. Up-regulation of C3 expression by TNF-n in endothelial
cells (P < 0.05 compared to unstimulated cells). In comparison (B) both
TNF-o and IL-la (P <0.05 for both) of up-regulate gene expression in rat
hepatoma cells.
at 94°C, one minute annealing at 65°C and two minutes extension!
synthesis at 72°C, and the reaction completed by a 10 minute
incubation at 72°C (DNA thermal cycler; Perkin-Elmer/Cetus,
Buckinghamshire, UK). The products were separated on a 1,2%
agarose gel and stained with ethidium bromide.
For quantification human GPI primers were included in the
reaction mixture as an internal control. The PCR cycle number
was in the linear range of amplification for both sets of primers as
assessed in preliminary experiments (data not shown). The
ethidium bromide stained gels were photographed and the bands
were scanned using the Qgel 1-D densitometry program. The
yield of specific product was expressed as a ratio of the internal
control.
Primer specificity
The specificity of the C3 primers was assessed by restriction
enzyme analysis. The PCR product was eluted from agarose gel by
microcentrifugation and used as the template for a second round
of PCR amplification. Approximately 0.5 xg of product was
digested by TaqI restriction enzyme and the products separated
on a 3% Nusieve agarose/1% agarose gel and stained with
ethidium bromide.
Inhibition of new protein synthesis
To assess the mechanism by which TNF-a up-regulated C3
gene expression cyeloheximide 5 xg/ml was added to the tissue
culture supernatant at the time of TNF-cs stimulation. After 24
hours mRNA was extracted and analyzed as described above, To
ensure that the cells remained viable in the presence of cyclohex-
imide, viability was assessed after a 24 hour incubation with
cycloheximide by a Trypan blue exclusion assay. Cycloheximide
abolishes any de novo protein synthesis and determines whether a
newly synthesized protein moiety is necessary to increase C3 gene
expression induced by TNF-a.
Metabolic labeling and immunoprecipitation
Five x 106 unstimulated or TNF-a stimulated endothelial cells
were labeled with 35S methionine as previously described [13].
Cells were washed and then pre-incubated for one hour in
methionine free RPM! and then for one hour in the presence of
250 jxCi/ml 35S methionine. Supernatants were collected at this
time point or after a further six hour incubation in the presence of
excess (X10) cold methionine. Cell lysates were solubilized in 1%
Triton, 0.5% deoxycholic acid, 10mM EDTA, 2 mivi phenylmethyl-
sulfonyl flouride, 100 xg/ml leupeptin and pepstatin A in PBS.
Supernatants and lysates were incubated overnight at 4°C with a
1/25 dilution of anti-C3 and immune complexes precipitated with
staphylococcal protein A. Following the washing, immune com-
plexes were released by boiling and separated on a 7.5% SDS-
PAGE gel under reducing conditions as described by Laemmli
[28]. The gels were fixed, amplified, dried and exposed to X-ray
film at —70°.
Statistics
Data were analysed using the Student's t-test. P values are as
stated.
Results
Complement gene expression in endothelial cells
A PCR product, 272 base pairs in length corresponding to C3
mRNA, was detected from unstimulated endothelial cells at 28
cycles of amplification. The specificity of the primers was con-
firmed with a TaqI restriction enzyme digestion of the PCR
product producing fragments of 167 and 105 bp as predicted from
the known sequence of C3 eDNA (Fig. 1). Non-reverse tran-
scribed RNA, as a negative control, gave no product. No product
representing the C4 gene product could be detected from endo-
thelial eDNA even after cytokine stimulation. C4 primers pro-
duced an easily detectable product from eDNA prepared from rat
liver as a positive control.
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Fig. 3. Time and dose response of C3 gene expression in TNF-cx stimulated cells. A. Time dependency of the endothelial response to TNF-a with a maximal
response seen after 12 hours. B. Response to increasing supernatant concentrations of TNF-a for a 24 hour incubation. Mean of duplicate experiments
shown. C. A typical gel showing an increase in the density of the 272 bp band of C3 PCR product compared to the internal GPI control (470 bp).
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Up-regulation of C3 gene expression by TNF-a
Twenty-four hours stimulation of the endothelial cells with
TNF-a resulted in approximately a fourfold (P < 0.05) increase in
the normalized C3/GPI ratio from gel densitometry. No signifi-
cant increase was seen with either IFN-y or IL-la. Comparing
these results to rat hepatoma cell culture, both TNF-a and IL-la
up-regulated C3 gene expression, but again, rat recombinant
IFN-y had no effect (Fig. 2).
The effect of TNF-a occurred in a time and dose dependent
fashion as illustrated in Figure 3.
Mechanism of TNF-cs action
When endothelial cells were cultured in the presence of TNF-a
in combination with cycloheximide the increase in the C3/GPI
ratio seen with TNF-a alone was abolished (Fig. 4). This would
therefore suggest that the action of TNF-a on these cells is
dependent on the synthesis of a second protein. Cell viability in
the presence of cycloheximide (94.6%) was comparable to control
cultures (94.4%).
Biosynthesis of the C3 protein
To confirm that the C3 transcript resulted in biosynthesis of
protein the cells were metabolically labeled and the C3 precipi-
tated with a specific anti-sera. This was done with both unstimu-
lated and TNF-a stimulated cells (Fig. 5).
Intracellular C3 precipitated from the cell lysates immediately
after the labeling period was characterized by a 185 kDa chain
corresponding to the pro-C3 chain. This product diminished from
the lysates during the six-hour chase period as the pro-chain was
processed and secreted from the cell. After the six-hour chase
period the supernatants demonstrated two bands of 110 and 75
kDa corresponding to the a and 13 chains of the C3 molecule.
Although this process could be demonstrated in the unstimu-
lated endothelial cells, in parallel experiments the amount of
labeled C3 was greater in the TNF-a stimulated cells. This
confirms that the increase in C3 mRNA is reflected in an increase
in protein biosynthesis.
Discussion
Previously it has been assumed that the complement deposited
in the glomerulus during immune mediated injury was derived
from the circulation. But it is now clear that the kidney has the
capacity to synthesize some, if not all, of the components of the
complement cascade. This is a property it shares with other tissues
including the synovium [29] and CNS [30]. In vitro experiments
have shown that mesangial, tubular and glomerular epithelial cells
synthesize complement proteins both constitutively and following
stimulation with pro-inflammatory cytokines. The factors regulat-
ing complement gene expression at extra-hepatic sites, in some
cases, differ from those in the liver, suggesting some degree of
tissue specificity. We have demonstrated that the glomerular
endothelial cell also has the capacity to synthesize C3. Constitu-
tive synthesis occurs at a low level but is considerably enhanced by
stimulation with the cytokine TNF-a. Other cytokines, in partic-
ular IL-i, increased mRNA expression in hepatocytes but not in
the endothelial cells, again demonstrating the tissue specificity of
cytokine up-regulation of complement gene expression.
During the induction of immune injury the endothelium will be
exposed to many cytokines, including TNF-a [31]. TNF-a could
be synthesized either by infiltrating cells or native glomerular
cells, particularly macrophages and mesangial cells, respectively
[32], potentially producing concentrations comparable to those
used in vitro. Therefore, it is likely that the production of C3 by
the endothelium will be up-regulated during disease. This may be
an additional mechanism by which TNF-a contributes to glomer-
ular injury. It has been demonstrated that the intrarenal expres-
sion of complement genes is increased during immune complex
disease and acute transplant rejection in humans and in experi-
mental models of renal disease in animals. The glomerular
endothelial cell must now also be considered as a possible source
of increased complement synthesis during inflammatory injury.
There is some in vivo evidence to support this with the detection
of both C3 mRNA in glomerular endothelium during lupus
nephritis [33] and the presence of donor specific C3 protein in
vascular endothelium during transplant rejection [34].
Nevertheless, the liver remains the main source of circulating
complement and it is unlikely that local tissue synthesis, even
when stimulated, contributes significantly to this pool. Therefore,
any contribution of locally synthesized complement to the patho-
genesis of disease would occur within the micro-environment of
the cell and its neighbors.
The glomerular endothelial cell forms part of the filtration
barrier separating the internal environment from the urinary
space. Because of this specialized function it differs from endo-
thelial cells from other sites, not only in its structure but also the
degree to which it is exposed to antigenic material. It also acts as
an interface between other glomerular structures and the blood
borne mediators of inflammation including antibodies, leukocytes
and complement. During the development of inflammation the
endothelium plays an active role particularly in the adhesion and
migration of leukocytes to the site of tissue damage. Intact
endothelial function is also essential for homeostasis, including
control of the clotting and complement cascades.
The activation of the complement cascade is a powerful medi-
ator of tissue inflammation. The endothelial cell is protected from
complement mediated lysis by the presence of membrane bound
inhibitors of complement activation such as decay accelerating
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Fig. 4. Cycloheximide suppression of TNF-a induced C3 expression. This
demonstrates the loss of the TNF-cs stimulatory effect when the incubation
occurred in the presence of cycloheximide.
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Fig. 5. Metabolic labelling and immunoprecipitation of C3. Analysis on SDS PAGE under reducing conditions of unstimulated cells (A) and TNF-a
stimulated cells (B). The starting cell number was the same in both experiments. Lane I in each case is immediately after the labeling period, and lane
2 follows the 6 hour chase period. In the TNF-cx stimulated cells, there is an increase in the intensity of the pro-C3 band in the cell lysates and of the
a and [3 chains in the supernatants.
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factor [351. However, the deposition of complement split products
or sub-lytic concentrations of membrane attack complex can alter
endothelial cell function. The presence of endothelial cell bound
C3b facilitates the binding of leukocytes [36] via receptors on their
surface. Membrane attack complex (MAC) deposition at levels
insufficient to kill the cell can affect endothelial prostaglandin
metabolism [37], induce the production of growth factors [38] and
have pro-thrombotic effects [39]. C3 synthesized from within the
endothelium might bind to the membrane of cells in which it is
produced. This could enhance leukocyte adhesion and through
the alternative pathway lead to assembly of the MAC.
C3 synthesized by the endothelium could potentially influence
immune injury in a number of other different ways. The split
products of C3 and other components have anaphylotoxic prop-
erties leading to increased vascular permeability and vasodilation
which may be of particular importance if produced from within
the vessel wall. Similarly, chemotactic activity could be enhanced
if a gradient is created as a result of complement synthesized at
the site of tissue injury. Complement by increasing soluhility and
enhancing uptake of immune complexes protects against immune
complex disease. Humans with complement deficiencies show an
increased incidence of immune complex disease [5]. In one animal
model of immune complex disease the site of deposition of
complexes was altered by depletion with cobra venom factor,
suggesting a role for complement in immune complex handling
within the glomerulus [40]. Locally synthesized C3 could therefore
have a protective role in the removal of immune complexes. The
endothelium can express both class I and II major histocompat-
ability antigens and potentially can present antigen to circulating
lymphocytes. It is now established that the presence of comple-
ment facilitates antigen presentation.
The exact mechanism by which TNF-cs influences cellular
metabolism is unknown. From the data we present here, it would
appear that TNF- increases C3 biosynthesis by increasing gene
transcription rather than stabilizing the pre-existing message. This
process requires the synthesis of a new protein moiety that could
represent a transcription factor or a second signalling peptide.
It is not clear why C3 but not C4 is synthesized by these
endothelial cells. C3 is pivotal in both the alternative and classical
pathways as well as possessing other immunomodulatory func-
tions, C4 being confined to the classical pathway. It may be that
C3 synthesized by the endothelium has functions independent of
the classical pathway, some of which are discussed above.
C3 is not solely derived from the liver but can he synthesized by
the kidney and is up-regulated by disease. This is now well
documented, hut what is less clear is the contribution made by
tissue derived complement during the pathogenesis of disease. It
is possible to attribute both protective or injurious roles, but as yet
we are some distance away from defining its exact function.
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